EyePoint Pharmaceuticals (FRA:PV3) Change In Payables And Accrued Expense : €1.33 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is EyePoint Pharmaceuticals Change In Payables And Accrued Expense?

EyePoint Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was €0.67 Mil. It means EyePoint Pharmaceuticals's Accounts Payable & Accrued Expense increased by €0.67 Mil from Sep. 2023 to Dec. 2023 .

EyePoint Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €1.39 Mil. It means EyePoint Pharmaceuticals's Accounts Payable & Accrued Expense increased by €1.39 Mil from Dec. 2022 to Dec. 2023 .

EyePoint Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for EyePoint Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Change In Payables And Accrued Expense Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

4.14

1.54

7.50

1.13

1.39

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-0.46	-2.12	5.49	-2.71	0.67

EyePoint Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.33 Mil.

EyePoint Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (FRA:PV3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (FRA:PV3) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

EYPT:USA PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (FRA:PV3) Headlines

No Headlines